OBJECTIVES: AbbVie provides a PSP to support adalimumab (ADA)-treated patients with laboratory tests, nurse support, injection training, pen disposal, and medication reminders. We investigated associations between PSP and rate of ADA persistence among ADA-treated patients with rheumatoid arthritis (RA) in Uruguay. METHODS: A retrospective study was conducted (03/2010–11/2014) among adults with RA who initiated ADA and opted-in to the PSP (PSP-users) versus patients who initiated ADA and did not opt-in to PSP (non-users). All patients were evaluated using AbbVie’s PSP database and available dispensing data at 12 and 24 months following initiation. For PSP-users, the index date was the date of enrollment. ADA initiation was used to assign index dates to non-users. The difference in persistence (time from index date to ADA discontinuation date) between PSP-users and non-users was evaluated. Discontinuation was defined as no ADA dispensing for 3 consecutive months. No formal statistical tests were required because the full population of ADA-treated patients in Uruguay was analyzed, eliminating the need for hypothesis testing. RESULTS: A total of 210 (98 PSP-users, 112 non-users) and 136 (44 PSP-users, 92 non-users) patients were available for the 12- and 24-month analyses, respectively. By 12 months, PSP-users persisted on ADA for an average of 11 months versus 9.98 months for non-users. Persistence on ADA continued to be higher at 24-months with PSP-users using ADA for an average of 20.0 months versus 16.2 months for non-users, resulting in 23% more time spent on therapy for PSP-users. CONCLUSIONS: Enrollment in AbbVie’s PSP resulted in a higher persistence for ADA among Uruguayan patients with RA, demonstrating that it is an important tool for helping patients adhere to their medication. Additional studies are needed to evaluate PSP impact on disease control, patients’ and physicians’ preferences, and associated healthcare resource utilization.